AR077638A1 - Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad - Google Patents
Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidadInfo
- Publication number
- AR077638A1 AR077638A1 ARP100102424A ARP100102424A AR077638A1 AR 077638 A1 AR077638 A1 AR 077638A1 AR P100102424 A ARP100102424 A AR P100102424A AR P100102424 A ARP100102424 A AR P100102424A AR 077638 A1 AR077638 A1 AR 077638A1
- Authority
- AR
- Argentina
- Prior art keywords
- obesity
- diabetes
- pyridine
- prepare
- treatment
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 1
- JJWOMLRJNXMLSO-UHFFFAOYSA-N 1-methylsulfonylpiperidine Chemical compound CS(=O)(=O)N1CCCCC1 JJWOMLRJNXMLSO-UHFFFAOYSA-N 0.000 abstract 1
- AJJISMLYIMQAKP-OAHLLOKOSA-N 5-[4-[(2r)-4-(3-fluoro-4-methylsulfonylphenoxy)butan-2-yl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=C(F)C(=CC=2)S(C)(=O)=O)=N1 AJJISMLYIMQAKP-OAHLLOKOSA-N 0.000 abstract 1
- 229940100607 GPR119 agonist Drugs 0.000 abstract 1
- 125000004171 alkoxy aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382114 | 2009-07-15 | ||
| US24544509P | 2009-09-24 | 2009-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077638A1 true AR077638A1 (es) | 2011-09-14 |
Family
ID=43449712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100102424A AR077638A1 (es) | 2009-07-15 | 2010-07-06 | Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8207344B2 (enExample) |
| EP (1) | EP2454251A1 (enExample) |
| JP (1) | JP5715127B2 (enExample) |
| KR (1) | KR101365854B1 (enExample) |
| CN (1) | CN102471313B (enExample) |
| AR (1) | AR077638A1 (enExample) |
| AU (1) | AU2010273642B2 (enExample) |
| BR (1) | BRPI1015921A2 (enExample) |
| CA (1) | CA2764906C (enExample) |
| CO (1) | CO6480977A2 (enExample) |
| CR (1) | CR20120012A (enExample) |
| DO (1) | DOP2012000006A (enExample) |
| EA (1) | EA020540B1 (enExample) |
| EC (1) | ECSP12011606A (enExample) |
| IL (1) | IL216776A0 (enExample) |
| MA (1) | MA33428B1 (enExample) |
| MX (1) | MX2012000704A (enExample) |
| NZ (1) | NZ597125A (enExample) |
| PE (1) | PE20121045A1 (enExample) |
| SG (1) | SG177646A1 (enExample) |
| TN (1) | TN2012000002A1 (enExample) |
| TW (1) | TWI429634B (enExample) |
| WO (1) | WO2011008663A1 (enExample) |
| ZA (1) | ZA201200227B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS20050532A (sr) | 2003-01-14 | 2007-12-31 | Arena Pharmaceuticals Inc., | Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| JP2013522279A (ja) | 2010-03-18 | 2013-06-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ |
| CN103221410B (zh) | 2010-09-22 | 2017-09-15 | 艾尼纳制药公司 | Gpr119受体调节剂和对与其相关的障碍的治疗 |
| US20140018371A1 (en) * | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US8957062B2 (en) | 2011-04-08 | 2015-02-17 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| WO2012170702A1 (en) * | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| KR101913619B1 (ko) | 2011-06-09 | 2018-12-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Gpr-119의 조절제로서의 신규한 화합물 |
| EP2720544B1 (en) | 2011-06-16 | 2016-12-21 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment |
| WO2013048916A1 (en) * | 2011-09-30 | 2013-04-04 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| EP2771000B1 (en) | 2011-10-24 | 2016-05-04 | Merck Sharp & Dohme Corp. | Substituted piperidinyl compounds useful as gpr119 agonists |
| WO2013062835A1 (en) * | 2011-10-24 | 2013-05-02 | Merck Sharp & Dohme Corp. | Substituted piperidinyl compounds useful as gpr119 agonists |
| CA2855009C (en) | 2011-11-15 | 2019-07-09 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as gpr119 agonists |
| WO2013187646A1 (en) * | 2012-06-12 | 2013-12-19 | Chong Kun Dang Pharmaceutical Corp. | Piperidine derivatives for gpr119 agonist |
| AU2013290100A1 (en) | 2012-07-11 | 2015-01-29 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| WO2014052619A1 (en) * | 2012-09-27 | 2014-04-03 | Irm Llc | Piperidine derivatives and compositions as modulators of gpr119 activity |
| HUE045926T2 (hu) | 2013-11-26 | 2020-01-28 | Chong Kun Dang Pharmaceutical Corp | Amid-származékok GPR119 agonistákhoz |
| KR101651505B1 (ko) * | 2014-05-02 | 2016-08-29 | 현대약품 주식회사 | 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
| CA3002540C (en) | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
| JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩 |
| CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
| JP7397011B2 (ja) | 2018-06-06 | 2023-12-12 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１ｐ１受容体に関連する状態を治療する方法 |
| MX2022010548A (es) | 2020-02-28 | 2022-09-23 | Kallyope Inc | Agonistas de gpr40. |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS20050532A (sr) * | 2003-01-14 | 2007-12-31 | Arena Pharmaceuticals Inc., | Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija |
| EP2059517A1 (en) * | 2006-08-30 | 2009-05-20 | Biovitrum AB (publ) | Pyrimidine compounds for treating gpr119 related disorders |
| US7638541B2 (en) * | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| ES2499018T3 (es) * | 2007-09-20 | 2014-09-26 | Irm Llc | Compuestos y composiciones como moduladores de la actividad de GPR119 |
-
2010
- 2010-07-06 AR ARP100102424A patent/AR077638A1/es not_active Application Discontinuation
- 2010-07-08 TW TW099122534A patent/TWI429634B/zh not_active IP Right Cessation
- 2010-07-12 WO PCT/US2010/041645 patent/WO2011008663A1/en not_active Ceased
- 2010-07-12 PE PE2012000041A patent/PE20121045A1/es not_active Application Discontinuation
- 2010-07-12 AU AU2010273642A patent/AU2010273642B2/en not_active Ceased
- 2010-07-12 US US12/834,054 patent/US8207344B2/en not_active Expired - Fee Related
- 2010-07-12 NZ NZ597125A patent/NZ597125A/xx not_active IP Right Cessation
- 2010-07-12 SG SG2012002523A patent/SG177646A1/en unknown
- 2010-07-12 CN CN201080031375.4A patent/CN102471313B/zh not_active Expired - Fee Related
- 2010-07-12 BR BRPI1015921A patent/BRPI1015921A2/pt not_active IP Right Cessation
- 2010-07-12 EA EA201270169A patent/EA020540B1/ru not_active IP Right Cessation
- 2010-07-12 JP JP2012520691A patent/JP5715127B2/ja not_active Expired - Fee Related
- 2010-07-12 KR KR1020127000996A patent/KR101365854B1/ko not_active Expired - Fee Related
- 2010-07-12 MA MA34531A patent/MA33428B1/fr unknown
- 2010-07-12 CA CA2764906A patent/CA2764906C/en not_active Expired - Fee Related
- 2010-07-12 MX MX2012000704A patent/MX2012000704A/es active IP Right Grant
- 2010-07-12 EP EP10734412A patent/EP2454251A1/en not_active Withdrawn
-
2011
- 2011-12-05 IL IL216776A patent/IL216776A0/en unknown
- 2011-12-29 CO CO11181048A patent/CO6480977A2/es active IP Right Grant
-
2012
- 2012-01-02 TN TNP2012000002A patent/TN2012000002A1/en unknown
- 2012-01-09 CR CR20120012A patent/CR20120012A/es unknown
- 2012-01-11 ZA ZA2012/00227A patent/ZA201200227B/en unknown
- 2012-01-11 DO DO2012000006A patent/DOP2012000006A/es unknown
- 2012-01-13 EC EC2012011606A patent/ECSP12011606A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI429634B (zh) | 2014-03-11 |
| WO2011008663A1 (en) | 2011-01-20 |
| MA33428B1 (fr) | 2012-07-03 |
| TW201114757A (en) | 2011-05-01 |
| NZ597125A (en) | 2013-08-30 |
| JP5715127B2 (ja) | 2015-05-07 |
| KR20120024964A (ko) | 2012-03-14 |
| BRPI1015921A2 (pt) | 2016-04-26 |
| CN102471313A (zh) | 2012-05-23 |
| KR101365854B1 (ko) | 2014-02-21 |
| AU2010273642A1 (en) | 2012-01-19 |
| CA2764906A1 (en) | 2011-01-20 |
| PE20121045A1 (es) | 2012-08-09 |
| ECSP12011606A (es) | 2012-02-29 |
| DOP2012000006A (es) | 2012-01-31 |
| EA201270169A1 (ru) | 2012-06-29 |
| TN2012000002A1 (en) | 2013-09-19 |
| US8207344B2 (en) | 2012-06-26 |
| SG177646A1 (en) | 2012-02-28 |
| CO6480977A2 (es) | 2012-07-16 |
| CN102471313B (zh) | 2014-06-04 |
| ZA201200227B (en) | 2013-06-26 |
| MX2012000704A (es) | 2012-03-07 |
| CA2764906C (en) | 2014-06-10 |
| IL216776A0 (en) | 2012-03-01 |
| EA020540B1 (ru) | 2014-11-28 |
| EP2454251A1 (en) | 2012-05-23 |
| JP2012533546A (ja) | 2012-12-27 |
| US20110015199A1 (en) | 2011-01-20 |
| AU2010273642B2 (en) | 2014-03-13 |
| CR20120012A (es) | 2012-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077277A1 (es) | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer | |
| CL2007003726A1 (es) | Anticuerpos anti-receptor del factor del crecimiento similar a la insulina i (igf-ir); composicion farmaceutica que lo contiene; y su uso para tratar el cancer. | |
| CL2012001722A1 (es) | Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes. | |
| AR071187A1 (es) | Compuesto de arilmetil-tiazinamina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento de la enfermedad de alzheimer | |
| AR075104A1 (es) | Compuesto de piperazin-aril-purina, su uso para preparar un medicamento util para el tratamiento del dolor y composicion farmaceutica que lo comprende | |
| UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
| CL2008000198A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis. | |
| CL2007003261A1 (es) | Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, tales como esquizofrenia, | |
| CL2008001049A1 (es) | Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad. | |
| CL2009000394A1 (es) | Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer. | |
| CL2008001271A1 (es) | Compuestos derivados de heterociclos de nitrogeno y oxigeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, hiperglicemia, intolerancia a la glucosa, aterosclerosis, dislipidemia, obesid | |
| UY32884A (es) | 1-sustituido-4-(5-(fenil o heteroaril)metoxi)-pirimidin-2-il)piperazinas y piperidinas | |
| UY31863A (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
| CL2007003423A1 (es) | Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda | |
| CL2008001868A1 (es) | Compuestos derivados de n-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades inflamatorias del intestino, enfermedad alergica | |
| EA200970585A1 (ru) | Бензамидные производные как агонисты ер-рецепторов | |
| CL2013002414A1 (es) | Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension. | |
| CL2007002607A1 (es) | Compuestos derivados de aril-sulfonamida o piridin-sulfonamida; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de una enfermedad o trastorno mediado por las interacciones de los linfocitos, tales como artritis reumatoide, | |
| AR074632A1 (es) | Compuesto de amidofenoxiindazol, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util en el tratamiento de cancer | |
| BRPI0809667A2 (pt) | Composto, medicamento e composição farmacêutica que o contém e uso do composto | |
| AR068369A1 (es) | Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina" | |
| CL2007003440A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida | |
| GT201200164A (es) | "nuevos compuestos de espiropiperidina" | |
| CL2008002162A1 (es) | Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras. | |
| AR060974A1 (es) | Compuesto de 4-piridinona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende, proceso para su preparacion y proceso para la preparacion de un compuesto intermediario de utilidad en el anterior |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |